SCHEMBL29670816

SCHEMBL29670816

c1ccc2c(c1)OCc1cn[nH]c1-2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 1.00
LTK P29376 3/20 0.61
PLK4 O00444 2/20 0.61
DAPK3 O43293 2/20 0.61
PIM1 P11309 2/20 0.61
PDGFRA P16234 2/20 0.61
MAP2K2 P36507 2/20 0.61
FLT3 P36888 2/20 0.61
MAPK8 P45983 2/20 0.61
MAPK9 P45984 2/20 0.61
CSNK1A1 P48729 2/20 0.61
CDK8 P49336 2/20 0.61
CDK5 Q00535 2/20 0.61
MAP2K1 Q02750 2/20 0.61
PTK2 Q05397 2/20 0.61
MAP4K2 Q12851 2/20 0.61
ROCK1 Q13464 2/20 0.61
DYRK1A Q13627 2/20 0.61
PIM3 Q86V86 2/20 0.61
CAMK1D Q8IU85 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2544817 1.00 KMT2A (1.00) KMT2ALTKPLK4DAPK3PIM1
SCHEMBL18020288 0.77 KMT2A (0.62) KMT2ALTKPLK4DAPK3PIM1
SCHEMBL9538263 0.77 KMT2A (0.62) KMT2ALTKPLK4DAPK3PIM1
SCHEMBL24427604 0.77 KMT2A (0.62) KMT2ALTKPLK4DAPK3PIM1
SCHEMBL24427902 0.77 KMT2A (0.62) KMT2ALTKPLK4DAPK3PIM1
SCHEMBL12353645 0.76 KMT2A (0.61) KMT2ALTKPLK4DAPK3PIM1
SCHEMBL2920391 0.76 LTK (1.00) KMT2ALTKPLK4DAPK3PIM1
SCHEMBL1159880 0.76 LTK (0.72) KMT2ALTKPLK4DAPK3PIM1
SCHEMBL10176739 0.74 KMT2A (0.59) KMT2AMAOBMAOAALDH1A1KDM4E
SCHEMBL20955937 0.73 KMT2A (0.57) KMT2AMAOBALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598928-A1 FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF Radionetics Oncology, Inc. (US) 2025-08-13 EP claimed
WO-2024077006-A1 FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-04-11 WO claimed
EP-4598928-A1 FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF Radionetics Oncology, Inc. (US) 2025-08-13 EP disclosed
WO-2024077006-A1 FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-04-11 WO disclosed
US-11365199-B2 Pyrazole compounds as modulators of FSHR and uses thereof MERCK PATENT GMBH (DE) 2022-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365199-B2 Pyrazole compounds as modulators of FSHR and uses thereof FSHR, GNRHR, LHCGR KMT2A 2435/4885LTK 1402/4885PLK4 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.